Other substances

Piperaquine

An antimalarial.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
5
 AI-suggested references
0
 Clinical trials

General information

Piperaquine is an aminoquinoline antimalarial used mostly in combinational therapy (ChEBI, DrugBank).

Piperaquine on PubChem
Piperaquine on Wikipedia


Marketed as

In combination with artemisinin (ARTEKIN; DUO-COTECXIN)

 

Structure image - Piperaquine

C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial
Small molecule Non-randomized controlled open trial Moderate severity Mild severity 		Patients 4.62

In a fixed-dose with artemisinin. Significantly shortened time to SARS-CoV-2 negative viral RNA conversion. No significant lung CT imaging differences 10 days post-treatment between the treatment and the control group observed, however. Sample size: 23 + 18 control. Dosage: 750 mg on day 1; 375 mg on days 2-7.


 Nov/02/2020

AI-suggested references

Link Publication date
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.
Nov/02/2020
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach
Feb/04/2020
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.
Jul/06/2021
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Aug/14/2020
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
Jul/01/2021
Export (.csv)